Published in Cancer Weekly, July 6th, 2004
Objective tumor responses (by RECIST) in 48 patients after four cycles of taxane/platinum were documented in 42% of 31 patients given ProMune combination versus 24% of 17 patients given chemotherapy alone. The primary tumor response endpoints were supported by interim progression-free survival curves and CT tumor measurements.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.